# US 2021/0196864 A1 · Implantable sustained release device and a method of use therefor in the treatment of brain disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196864 A1
- Document ID: US20210196864A1
- Status: Published application
- Kind: A1
- Application number: 17/196,953
- Filed: 2021-03-09
- Published: 2021-07-01
- Earliest claimed: 2021-01-13
- Inventors: Adnan I. Qureshi
- Web page: https://patentgrep.com/patent/US20210196864A1

## CPC

- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61L 31/10: Macromolecular materials
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 2300/402: Anaestetics, analgesics, e.g. lidocaine
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A biocompatible and bioresorbable implantable device that is intended to be deployed in the middle meningeal artery through intra-arterial catheters and release an anesthetic agent for a prolonged period into the branches of the middle meningeal artery to treat severe headaches including migraine and trigeminal neuralgias. The implantable device may be a mesh with multiple helical loops, fenestrated collapsible hollow shell or spheroid, or folded sheath.

## Claims

### Claim 1

A method of treatment of recurrent headaches and/or trigeminal neuralgia, the method comprising the steps of:
providing a sustained release device that is configured to be implanted in a blood vessel supplying the dura mater in the brain,
wherein the sustained release device comprises an anesthetic agent, the sustained release device configured for sustained release of the anesthetic agent in the blood vessel for a prolonged period.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method further comprises the steps of:
implanting the sustained release device in the blood vessel.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the blood vessel is a middle meningeal artery.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the implanting step further comprises the step of:
receiving the sustained release device, in a collapsed form, in an arterial catheter; and
releasing the collapsed sustained release device into the blood vessel,
wherein the sustained release device in the blood vessel expands against the blood vessel, wherein the sustained release device is configured to expand to the predefined shape that remain in position in the blood vessel without immediate displacement.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the sustained release device comprises a frame and a coating on the frame, the coating comprises the anesthetic agent and a bioabsorbable polymer.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the frame is made of a biodegradable metal or a bioresorbable polymeric material.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the anesthetic agent is lidocaine or bupivacaine.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the prolonged period ranges from 3 to 6 months.

### Claim 9 (depends on 5)

The method according to claim 5, wherein the frame is having an elongated helical wire profile.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the frame is further having a mesh that extends between the helical wire loops, wherein the mesh and the helical wire loops assume parallel configuration perpendicular to the arterial wall, wherein the helical wire loops elongate in opposite direction resulting in decrease in a diameter of the frame, which can be inserted in the arterial catheter.

### Claim 11 (depends on 5)

The method according to claim 5, wherein the frame is having an additional base layer of a biocompatible material uniformly covering the frame, one or more layer of the coating is applied on the base layer.

### Claim 12 (depends on 11)

The method according to claim 11 wherein the biocompatible material is selected from a group consisting of poly n-butyl methacrylate, PTFE, PVDF-HFP, poly(styrene-bisobutylene-b-styrene), Parylene C, PVP, PEVA, SBS, PC, TiO2, or a combination thereof.

### Claim 13 (depends on 5)

The method according to claim 5, wherein the frame is made from material selected from a group consisting of magnesium alloy, polylactic acid, polycarbonate polymers, salicylic acid polymers or combination thereof.

### Claim 14 (depends on 5)

The method according to claim 5, wherein the sustained release device is further having a mesh that extends from the frame, the mesh having one or more layers of the coating.

### Claim 15 (depends on 5)

The method according to claim 5, wherein the frame is fenestrated collapsible hollow shell or spheroid.

### Claim 16 (depends on 5)

The method according to claim 5, wherein the frame is a rolled flat sheath having one or more layers of the coating, wherein the rolled flat sheath partly unfolds to expand in the blood vessel.

### Claim 17

A method of treatment of recurrent headaches and trigeminal neuralgia, the method comprising the steps of:
implanting a device in a middle meningeal artery for sustained release of an anesthetic agent for a prolonged period.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the anesthetic agent is lidocaine or bupivacaine.
